Cancer is now the second leading cause of death globally, with China accounting for approximately 20% of the world’s new cancer cases and 27% of the world’s cancer deaths, and with the number of people living with cancer rising by almost half a million in the last five years in the UK.

As part of the new Golden Era of relations, the UK and China have set out to work together on a wide range of global issues, with healthcare representing a vitally important new area of collaboration.

The China National Cancer Centre together with the Department for International Trade and the British Embassy Beijing, will bring together leading academic and industrial experts from the UK and China to tackle the global cancer challenge. Representatives will attend from a wide range of institutions including universities, hospitals, distributors, commercial organisations and research institutes. Attendees include AstraZeneca, Digital China Health, four UK National Health Service (NHS) Trusts and five leading UK Universities.

Exhibiting at the congress will be 30 UK companies working in the field of oncology to showcase the UK’s global expertise, and to seek new collaborations with Chinese organisations. State of the art and innovative products and services will be on display from top UK healthcare enterprises, covering the patient journey of prevention, diagnosis, primary and specialist care, rehabilitation and end of life care; and the science of the patient pathway for new therapies.

As home to many of the world’s most famous cancer hospitals and specialists, the UK is at the forefront of cancer research and the application of the very latest technologies to improve outcomes. Cancer survival in the UK has doubled in the last 40 years. The UK’s NHS strategy to improve cancer prevention, diagnosis, treatment and care until the end of life is committed to delivering the best possible outcomes for patients and their families.

More information about UK-China Oncology Congress, please go to http://www.ukchinaoc.com/